MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, will announce its second quarter 2023 financial results on Wednesday, August 2, 2023. The announcement will be followed by a conference call and audio webcast at 8:30 a.m. ET.
Participants can access the conference call live via webcast which will be available on the investor page of the company’s website at http://ir.interceptpharma.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. While not required, it is recommended you join 10 minutes prior to the event’s start. A replay of the call will be available on Intercept’s website following the completion of the call.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). For more information, please visit www.interceptpharma.com or connect with the Company on Twitter and LinkedIn.
Contact
For more information about Intercept, please contact:
Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
London, United Kingdom--(Newsfile Corp. - June 10, 2025) - Edison issues report on Global Fashion…
London, United Kingdom--(Newsfile Corp. - June 10, 2025) - Edison issues report on DUG Technology…
ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- Panacea Healthcare Solutions, a leading provider of financial,…
A Capitol Hill Convening to Advance Cross-Sector Strategies that Rebuild Human Connection and Strengthen Communities WASHINGTON,…
Issued on behalf of Avant Technologies Inc.Equity Insider News Commentary VANCOUVER, BC, June 10, 2025…
Unveiled live at Transform, LeanTaaS' hospital operations summit, the new product embeds key case building, managing,…